EVIDENCE

SureAdhere research & publications.

27 peer-reviewed studies supporting video directly observed therapy, from landmark randomized controlled trials to real-world implementation research across the US, Europe, Asia, and beyond.

SureAdhere evidence: peer-reviewed research
27
Peer-reviewed publications
10+
Countries represented in research
WHO
Global treatment guidelines informed
CDC
US treatment guidelines updated
FULL EVIDENCE BASE

Peer-Reviewed Publications

These peer-reviewed studies, spanning RCTs, cohort studies, and real-world implementation research, form the scientific foundation behind SureAdhere and have directly informed WHO and CDC treatment guidelines.

Location
Study Type
01
RCT
Burzynski J, Mangan JM, Lam CK, et al. JAMA Netw Open. 2022;5(1):e2144210.
Electronic DOT was non-inferior to in-person DOT (−2.6% difference) across 4 clinics and 216 patients, providing key evidence for inclusion of eDOT in the standard of care.
Jan 2022
USAMulti-state
02
Casalme DJO, Marcelo DB, et al. Int J Tuberc Lung Dis. 2022;26(8):760-765.
Aug 2022
PhilippinesAsia
03
Perry A, Chitnis A, Chin A, et al. Int J Tuberc Lung Dis. 2021;25(8):655-661.
Aug 2021
USAUrban
05
RCT
Ravenscroft L, Kettle S, Persian R, et al. Eur Respir J. 2020;56(2):2000493.
Aug 2020
MoldovaEurope
06
Burzynski J, Macaraig M, Nilsen D, Schluger NW. Int J Tuberc Lung Dis. 2020;24(7):735-736.
Jul 2020
USANew York City
07
Sekandi JN, Buregyeya E, Zalwango S, et al. ERJ Open Res. 2020;6(1):00175-2019.
82.2% of expected videos received; median adherence 85%; 92% of patients reported being very satisfied. VDOT proved feasible and acceptable in a resource-limited African setting.
Mar 2020
UgandaAfrica
08
Garfein RS, Liu L, Cuevas-Mota J, et al. Int J Tuberc Lung Dis. 2020;24(5):520-525.
May 2020
USACalifornia
09
Jul 2020
ChinaAsia
10
Jul 2020
CambodiaAsia
11
Bommakanti KK, Smith LL, Liu L, et al. BMC Public Health. 2020;20(1):81.
Jan 2020
USANew York City
12
Nov 2020
USAMulti-city
13
RCT
Story A, Aldridge RW, Smith CM, et al. Lancet. 2019;393(10177):1216-1224.
VOT was superior to in-person DOT (75% vs 60% completing 80%+ of scheduled observations) across 22 clinics: more acceptable, effective, and cheaper than DOT.
Mar 2019
UKLondon
14
Bendiksen R, Ovesen T, Asfeldt AM, et al. Tidsskr Nor Laegeforen. 2020;140(1).
Jan 2020
NorwayEurope
15
Sep 2019
IndiaAsia
16
Do D, Garfein RS, Cuevas-Mota J, Collins K, Liu L. JMIR Mhealth Uhealth. 2019;7(2):e11638.
Feb 2019
USACalifornia
17
Fraser H, Keshavjee S. Lancet. 2019;393(10177):1180-1181.
Mar 2019
GlobalCommentary
18
Dec 2019
USAReview
19
Garfein RS, Liu L, Cuevas-Mota J, et al. Emerg Infect Dis. 2018;24(10):1806-1815.
VDOT adherence was 93% vs 66% for in-person DOT, at 32% lower cost: feasible, acceptable, and achieving high adherence across 5 California health districts.
Oct 2018
USACalifornia
20
Lam CK, McGinnis Pilote K, Haque A, Burzynski J, Chuck C, Macaraig M. J Med Internet Res. 2018;20(11):e287.
Nov 2018
USANew York City
21
Apr 2018
USAMulti-site
22
May 2018
USAClinical Practice
23
Sinkou H, Hurevich H, Rusovich V, et al. Eur Respir J. 2017;49(3):1602049.
Mar 2017
BelarusEurope
24
Nguyen TA, Pham MT, Nguyen TL, et al. Int J Infect Dis. 2017;65:85-89.
71.1% of patients took all required doses; median 88.4% of doses correctly recorded. VDOT was feasible and resulted in high adherence in a resource-limited outpatient setting.
Dec 2017
VietnamAsia
25
Holzschuh EL, Province S, Johnson K, et al. MMWR Morb Mortal Wkly Rep. 2017;66(14):387-389.
Apr 2017
USAKansas
26
Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Int J Tuberc Lung Dis. 2016;20(5):588-593.
May 2016
USANew York City
27
Garfein RS, Collins K, Muñoz F, et al. Int J Tuberc Lung Dis. 2015;19(9):1057-1064.
Sep 2015
USA / MexicoBinational
No publications match your search. Try different terms or clear the filters.
GET STARTED

Learn how SureAdhere can amplify your program.

See how the evidence-backed SureAdhere platform can improve outcomes and reduce burden for your patients and care teams.

Schedule a demo Back to overview